The Lancet · Online First· Domenica Lorusso, Jérôme Martin-Babau, Floor Backes, Maria Pilar Barretina Ginesta, Jacob Korach, Shibani Nicum, Julian Wampfler, Jianqing Zhu, Monika Ducceschi, Toon Van Gorp, Magnus Frödin-Bolling, Flora Zagouri, Judith R Kroep, Isabelle Ray-Coquard, Vanda Salutari, Michelle D S Lightfoot, Todd Tillmanns, David M O’Malley, Kosei Hasegawa, Jung-Yun Lee, Gonzalo H Giornelli, Vanessa Samouëlian, Yoland Antill, Jundong Li, Shin Nishio, Jack Junjie Chan, Bradley J Monk, Chenxiang Li, Kristina Woodhouse, Robert Orlowski, Carmen García-Duran, Bhavana Pothuri, TroFuse-005/ENGOT-en23/GOG-3095 Investigators·· 2 小时前精选AI 评分72
TroFuse-005/ENGOT-en23/GOG-3095：Sacituzumab tirumotecan改善既往接受治疗的子宫内膜癌患者生存结局
[Articles] Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial
AI 导读
随机、开放标签III期试验TroFuse-005/ENGOT-en23/GOG-3095显示，sacituzumab tirumotecan（sac-TMT）较医生选择的治疗显著改善既往接受铂类化疗和免疫治疗的晚期或复发性子宫内膜癌患者的无进展生存期和总生存期。研究结果支持将sac-TMT作为这类有效治疗选择有限患者的新标准治疗；所提供摘要未列出样本量、随访时间或具体效应量。
推荐理由
研究聚焦铂类化疗和免疫治疗后有效选择有限的子宫内膜癌患者，以医生选择治疗为对照评估无进展生存期和总生存期获益。
来源：The Lancet · Online First · thelancet.com